The main concept of the MEDLEM project proposal
| Full title: | Cost-effective microfluidic electronic devices for optimal drug administration based on fractional pharmacokinetics for leukemia treatments |
|---|---|
| Acronym: | MEDLEM |
| Grant no: | 690876 |
| Type of action: | Marie Sklodowska-Curie Research and Inovation Staff Exchange(RISE) |
| Starting Date | 01/01/2016 |
| End Date | 31/12/2019 |
| Estimated eligible costs | 333.000,00 EUR |
| Maximum grant amount | 283.500,00 EUR |
The project entitled: “Cost-effective microfluidic electronic devices for optimal drug administration based on fractional pharmacokinetics for leukemia treatments”, with acronym MEDLEM, has a general objective to foster exchanging knowledge and sharing different culture and approaches in reaching high level of excellence, in research and innovation, in the framework of this field.
This project has approved for funding under the Horizon 2020 call: H2020-MSCA-RISE-2015.
The project is aimed at strengthening research collaboration through active networking, staff exchange and dissemination activities between four European organizations from Serbia, Germany and France as well as two non-European institutions from Thailand and Australia, in linking the fields of microfluidic electronic devices, optimal drug administration, fractional pharmacokinetics, and leukaemia treatments. The project will exploit complementary competences and synergies of the participants, and enable knowledge sharing via international/inter-sectoral mobility, based on secondments of research staff. The consortium offers a unique opportunity that creativity and entrepreneurship will flourish and will help exchanged personnel to turn creative ideas into innovative electronics products, reaching breakthroughs in modeling, drug administration and improvements in therapy protocols.